Wayne Pisano Buys 5,000 Shares of Altimmune (NASDAQ:ALT) Stock

Altimmune, Inc. (NASDAQ:ALT) Director Wayne Pisano bought 5,000 shares of Altimmune stock in a transaction dated Thursday, January 8th. The shares were bought at an average price of $4.08 per share, for a total transaction of $20,400.00. Following the completion of the transaction, the director directly owned 13,498 shares of the company’s stock, valued at $55,071.84. This represents a 58.84% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link.

Altimmune Stock Performance

Shares of Altimmune stock opened at $4.02 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 17.18 and a quick ratio of 17.18. The firm has a 50 day simple moving average of $4.48 and a 200 day simple moving average of $4.13. Altimmune, Inc. has a fifty-two week low of $2.90 and a fifty-two week high of $7.73. The firm has a market cap of $419.45 million, a P/E ratio of -3.76 and a beta of 0.04.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 54.79% and a negative net margin of 419,575.00%. Sell-side analysts predict that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ALT has been the topic of a number of research reports. Citigroup restated a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. Finally, Citizens Jmp dropped their target price on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research report on Friday, November 7th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $16.60.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ALT. Sherbrooke Park Advisers LLC acquired a new position in Altimmune in the third quarter valued at about $60,000. Sig Brokerage LP bought a new position in shares of Altimmune during the 3rd quarter valued at about $130,000. Millennium Management LLC grew its position in shares of Altimmune by 7,160.7% in the 3rd quarter. Millennium Management LLC now owns 367,582 shares of the company’s stock valued at $1,386,000 after purchasing an additional 372,788 shares during the period. Brevan Howard Capital Management LP increased its stake in Altimmune by 67.4% during the 3rd quarter. Brevan Howard Capital Management LP now owns 222,942 shares of the company’s stock worth $840,000 after purchasing an additional 89,733 shares in the last quarter. Finally, Two Sigma Investments LP raised its holdings in Altimmune by 356.6% during the 3rd quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock worth $7,528,000 after buying an additional 1,559,562 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.